<DOC>
	<DOCNO>NCT01076335</DOCNO>
	<brief_summary>The goal clinical research study find therapy use docetaxel chemotherapy hormonal therapy take schedule surgery beneficial treatment prostate cancer . The safety combination also study .</brief_summary>
	<brief_title>Neoadjuvant Hormones + Docetaxel Node-Positive Prostate Cancer</brief_title>
	<detailed_description>Advanced prostate cancer may responsive combination hormonal chemotherapy treatment . Researchers believe use chemotherapy hormonal therapy schedule surgery may help affect delay progression prostate cancer . Before surgery , image study , include chest x-ray , CT scan bone scan . You may also MRI scan . These test do check status disease . You also 3 tablespoon blood drawn routine blood test , treatment . All treatment give outpatient basis . Treatment start soon possible , within 14 day registration . You receive hormonal treatment month 12 month surgery . Hormonal treatment continue surgery . You give dexamethasone , Benadryl® ( diphenylhydramine ) Pepcid® ( famotidine ) , vein arm central line vein therapy begin docetaxel Day 1 first treatment cycle . Dexamethasone help decrease bone marrow inflammation . Diphenhydramine help prevent allergic reaction . Famotidine protect stomach irritation decrease amount acid stomach . Docetaxel give needle vein ( IV ) week first 4 week 6-week period ( call study cycle ) . Each dose docetaxel take hour give . The total treatment time complete docetaxel 3 study cycle ( 18 week ) . Before 6-week study cycle docetaxel , come clinic physical exam routine blood test ( 2 tablespoon ) . After treatment docetaxel hormone , operation remove prostate gland tumor . Your doctor discuss surgical procedure detail explain risk operation . You need sign separate consent form undergo surgical procedure . After surgery , closely checked possible side effect . After completion treatment , monitor every 3 month first year every 6 month second year . You also 2 tablespoon blood drawn routine blood test monitoring every follow-up visit . This investigational study . Docetaxel hormone treatment use study FDA approve medication treatment prostate cancer . Up 40 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>1 . Patients adenocarcinoma prostate opinion surgeon could resectable response systemic therapy . Ductal carcinoma variant include . 2 . All patient must regard acceptable anesthetic risk radical prostatectomy confirm intention undergo radical prostatectomy end neoadjuvant therapy . 3 . Zubrod performance status 2 well . 4 . All patient must thorough tumor stag meet one follow criterion : ) Either lymph node biopsy lymph node dissection demonstrate presence lymph node metastasis . b ) Pelvic retroperitoneal lymphadenopathy &gt; /= 2.0 cm visualize CT scan ( biopsy require &gt; /= 2.0 cm typical distribution ) c ) Primary tumor Gleason score &gt; /= 8 serum PSA concentration &gt; /= 25 ng/ml , indicate high risk occult lymph node metastasis . 5 . ( # 4 cont 'd ) ) Primary tumor stage T3 Gleason score &gt; /= 7 , indicate high risk occult lymph node metastasis . e ) Primary tumor stage T4 indicate high risk occult lymph node metastasis . 6 . Prior hormonal therapy 6 month permit . No concurrent ketoconazole permit . 7 . Patients must adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500/mm^3 platelet count &gt; 100,000/mm^3 ; adequate hepatic function define total bilirubin &lt; 1.5 mg/dl AST/ALT &lt; 2X upper limit normal ; adequate renal function define serum creatinine clearance &gt; 40 cc/min ( measure calculate ) . 8 . Patients must sign informed consent indicate aware investigational nature study , keep policy institution . 9 . All patient must evaluate Department Urology Department Genitourinary Medical Oncology prior sign inform consent . 1 . Patients small cell sarcomatoid histology . 2 . Patients clinical radiological evidence bone extranodal metastasis ( M1b M1c ) . 3 . Prior chemotherapy . 4 . Patients severe uncontrolled intercurrent infection . 5 . Patients New York Heart Association ( NYHA ) Class III/IV congestive heart failure , unstable angina history myocardial infarction within last 6 month . 6 . Contraindications corticosteroid . 7 . Uncontrolled severe hypertension , persistently uncontrolled diabetes mellitus , oxygendependent lung disease , chronic liver disease HIV infection . 8 . Second malignancy ( exclude nonmelanoma skin cancer ) unless diseasefree 3 year . 9 . Overt psychosis , mental disability otherwise incompetent give inform consent .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Neoadjuvant Hormonal Therapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Radical Prostatectomy</keyword>
	<keyword>Node-positive Prostate Cancer</keyword>
	<keyword>Androgen-dependent prostate cancer</keyword>
	<keyword>Lymph node metastasis</keyword>
</DOC>